• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Use of recombinant human interferon alpha-2a in the management of a dog with epitheliotropic lymphoma.

作者信息

Tzannes Sophia, Ibarrola Patricia, Batchelor Daniel J, Burrow Rachel D, Blackwood Laura

机构信息

Department of Clinical Veterinary Science, Small Animal Teaching Hospital, University of Liverpool, Leahurst, Chester High Road, Neston, Cheshire, CH647TE, United Kingdom.

出版信息

J Am Anim Hosp Assoc. 2008 Sep-Oct;44(5):276-82. doi: 10.5326/0440276.

DOI:10.5326/0440276
PMID:18762565
Abstract

An 8-year-old, mixed-breed dog with preputial epitheliotropic lymphoma was initially treated with cyclophosphamide, vincristine, and prednisolone. A short-term partial response was followed by disease progression after 4 weeks. Recombinant human interferon alpha-2a was administered starting at week 7. The interferon therapy resulted in rapid resolution of clinical signs and a 10-week disease-free interval. The lymphoma recurred at 17 weeks and did not respond to rescue chemotherapy. Additional oral lesions were treated with localized radiotherapy followed by increased dosages of interferon. This additional interferon treatment resulted in another 12 weeks of stable disease.

摘要

相似文献

1
Use of recombinant human interferon alpha-2a in the management of a dog with epitheliotropic lymphoma.
J Am Anim Hosp Assoc. 2008 Sep-Oct;44(5):276-82. doi: 10.5326/0440276.
2
Primary malignant lymphoma of the urinary bladder in a dog: longterm remission following treatment with radiation and chemotherapy.一只犬膀胱原发性恶性淋巴瘤:放疗和化疗后长期缓解
Schweiz Arch Tierheilkd. 2008 Nov;150(11):565-9. doi: 10.1024/0036-7281.150.11.565.
3
Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study.145只淋巴瘤犬首次缓解和生存的影响因素:一项回顾性研究
J Am Anim Hosp Assoc. 2000 Sep-Oct;36(5):404-9. doi: 10.5326/15473317-36-5-404.
4
Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.狗恶性淋巴瘤的 13 周剂量递增同步联合化疗方案。
Vet Rec. 2010 Nov 6;167(19):744-8. doi: 10.1136/vr.c5081.
5
Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?维持化疗是否适用于犬恶性淋巴瘤的治疗?
J Vet Intern Med. 1992 Jan-Feb;6(1):3-10. doi: 10.1111/j.1939-1676.1992.tb00979.x.
6
Epitheliotropic cutaneous lymphoma (mycosis fungoides) in a dog.犬上皮嗜皮性皮肤淋巴瘤(蕈样霉菌病)
J Vet Sci. 2006 Mar;7(1):97-9. doi: 10.4142/jvs.2006.7.1.97.
7
Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.联合化疗治疗犬胃肠道淋巴瘤的疗效
J Vet Intern Med. 2009 Mar-Apr;23(2):317-22. doi: 10.1111/j.1939-1676.2008.0270.x. Epub 2009 Feb 2.
8
Use of isotretinoin and etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs.
J Am Vet Med Assoc. 1993 Feb 1;202(3):387-91.
9
What is your diagnosis? Ocular lymphoma.你的诊断是什么?眼淋巴瘤。
J Small Anim Pract. 2003 Dec;44(12):523, 553-4.
10
Treatment of canine lymphoma with COPLA/LVP.用COPLA/LVP治疗犬淋巴瘤。
J Am Anim Hosp Assoc. 2000 Sep-Oct;36(5):395-403. doi: 10.5326/15473317-36-5-395.

引用本文的文献

1
Identification of interferon-stimulated response elements (ISREs) in canines.犬类中干扰素刺激反应元件(ISREs)的鉴定。
BMC Vet Res. 2025 Mar 1;21(1):128. doi: 10.1186/s12917-025-04577-3.
2
Clinical response to isotretinoin and interferon-α of two dogs with cutaneous epitheliotropic T-cell lymphoma: a case report.两只患有皮肤亲上皮性T细胞淋巴瘤的犬对异维A酸和α干扰素的临床反应:病例报告
BMC Vet Res. 2018 Dec 4;14(1):382. doi: 10.1186/s12917-018-1710-y.
3
Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour.
犬传染性性病肿瘤的瘤内重组人干扰素α-2a与长春新碱联合治疗
Vet Med Sci. 2018 Nov;4(4):364-372. doi: 10.1002/vms3.119. Epub 2018 Aug 17.